Skip to main content
NMRA
NASDAQ Life Sciences

Neumora Q3: $85.7M Cash, No Runway Guidance, NMRA-215 IND Filed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.421
Mkt Cap
$80.589M
52W Low
$0.315
52W High
$3.65
52W Position info
33% above low
Off High info
88% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

NMRA sits 33% above its 52-week low of $0.315 on light trading volume (0.3× avg).

Summary

Neumora reported Q3 cash of $85.7 million and a $34.4 million net loss, declined to update runway guidance, and disclosed an FDA IND submission for NMRA-215 plus Phase 2-enabling NMRA-511 data.


Key Events · Earnings and Guidance · NMRA

  • Q3 Net Loss Narrows to $34.4M

    Net loss was $34.4 million versus $56.8 million a year earlier, as R&D fell to $22.6 million from $40.5 million and G&A to $10.8 million from $12.2 million.

  • Cash Falls to $85.7M, No Runway Guidance

    Cash and equivalents were $85.7 million at September 30, 2026, down from $182.5 million at December 31, 2025; the company declined to provide updated financial runway guidance and said it will require substantial additional funding.

  • NMRA-215 IND Submitted to FDA

    Neumora filed an IND for NMRA-215, an oral NLRP3 inhibitor for obesity and cardiometabolic disease; preclinical data showed up to 19% weight loss as monotherapy and up to 26% with semaglutide.

  • NMRA-511 Phase 2 Enabled

    The 30 mg BID MAD expansion cohort in healthy elderly participants showed no serious adverse events and dose-proportional exposure versus the 20 mg BID Phase 1b dose; the program is Phase 2 enabled.


Analysis · NMRA · Life Sciences

This is less an earnings story than a survival story. Cash fell to $85.7 million from $182.5 million at year-end 2025, and the company explicitly declined to give updated runway guidance while saying it will need substantial additional funding — against a going-concern warning previously disclosed in the August 10-Q and an October 26 Nasdaq minimum-bid notice. The pipeline news is real: an IND for NMRA-215 in obesity and Phase 2-enabling NMRA-511 data give the company something to raise money against. But with a $34.4 million quarterly net loss, the cash balance covers roughly two and a half quarters at the current burn, so a financing is the next event that matters.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NMRA was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.6M. The 52-week trading range was $0.32 to $3.65. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NMRA - Latest Insights

NMRA
Nov 16, 2026, 8:15 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.4206
Real-time Price: $0.4206 info
Change: $0 (0%) info
Market Cap: $80.589M info
NMRA
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.4206
Real-time Price: $0.4206 info
Change: $0 (0%) info
Market Cap: $80.589M info
NMRA
Oct 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3672
Real-time Price: $0.4206 info
Change: +$0.0534 (+15%) info
Market Cap: $80.589M info
NMRA
Aug 14, 2026, 7:23 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.65
Real-time Price: $0.4206 info
Change: -$1.23 (-75%) info
Market Cap: $80.589M info
NMRA
Aug 14, 2026, 7:13 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $0.4206 info
Change: -$1.23 (-75%) info
Market Cap: $80.589M info